Personalis, Inc. PSNL
We take great care to ensure that the data presented and summarized in this overview for Personalis, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PSNL
View all-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.07MShares$8.13 Million0.06% of portfolio
-
Black Rock Inc. New York, NY3.28MShares$4.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.9MShares$2.55 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.1MShares$1.47 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA992KShares$1.33 Million0.01% of portfolio
-
Nikko Asset Management Americas, Inc.978KShares$1.31 Million0.01% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.978KShares$1.31 Million0.0% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ822KShares$1.1 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il508KShares$680,0990.0% of portfolio
-
State Of Michigan Retirement System494KShares$661,6890.0% of portfolio
Latest Institutional Activity in PSNL
Top Purchases
Top Sells
About PSNL
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
Insider Transactions at PSNL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 17
2024
|
Stephen Michael Moore SVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,731
-2.39%
|
$1,731
$1.38 P/Share
|
May 17
2024
|
Aaron Tachibana CFO AND COO |
SELL
Open market or private sale
|
Direct |
1,333
-0.72%
|
$1,333
$1.38 P/Share
|
May 17
2024
|
Richard Chen CHIEF MEDICAL OFFICER AND EVP |
SELL
Open market or private sale
|
Direct |
940
-0.7%
|
$940
$1.38 P/Share
|
Apr 30
2024
|
Stephen Michael Moore SVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,523
-5.88%
|
$4,523
$1.37 P/Share
|
Mar 01
2024
|
Woodrow A Myers Jr |
BUY
Open market or private purchase
|
Direct |
10,000
+27.69%
|
$10,000
$1.67 P/Share
|
Jan 29
2024
|
Richard Chen CHIEF MEDICAL OFFICER AND EVP |
SELL
Open market or private sale
|
Direct |
526
-0.41%
|
$526
$1.37 P/Share
|
Jan 29
2024
|
Aaron Tachibana CFO AND COO |
SELL
Open market or private sale
|
Direct |
716
-0.39%
|
$716
$1.37 P/Share
|
Dec 15
2023
|
Aaron Tachibana CFO AND COO |
SELL
Open market or private sale
|
Direct |
6,747
-3.51%
|
$6,747
$1.47 P/Share
|
Dec 15
2023
|
Richard Chen CHIEF MEDICAL OFFICER AND EVP |
SELL
Open market or private sale
|
Direct |
4,708
-3.51%
|
$4,708
$1.47 P/Share
|
Dec 15
2023
|
Stephen Michael Moore SVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,476
-1.88%
|
$1,476
$1.47 P/Share
|
Nov 16
2023
|
Richard Chen CHIEF MEDICAL OFFICER AND EVP |
SELL
Open market or private sale
|
Direct |
940
-0.75%
|
$940
$1.04 P/Share
|
Nov 16
2023
|
Aaron Tachibana CFO AND COO |
SELL
Open market or private sale
|
Direct |
1,344
-0.7%
|
$1,344
$1.04 P/Share
|
Nov 16
2023
|
Stephen Michael Moore SVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,722
-2.15%
|
$1,722
$1.04 P/Share
|
Nov 01
2023
|
Christopher M Hall PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
20,459
-9.09%
|
$0
$0.93 P/Share
|
Jul 31
2023
|
Richard Chen CHIEF MEDICAL OFFICER AND EVP |
SELL
Open market or private sale
|
Direct |
485
-0.39%
|
$970
$2.26 P/Share
|
Jul 31
2023
|
Aaron Tachibana CFO AND COO |
SELL
Open market or private sale
|
Direct |
662
-0.34%
|
$1,324
$2.26 P/Share
|
Jun 16
2023
|
Aaron Tachibana CFO AND COO |
SELL
Open market or private sale
|
Direct |
6,904
-3.44%
|
$13,808
$2.07 P/Share
|
Jun 16
2023
|
Richard Chen CHIEF MEDICAL OFFICER AND EVP |
SELL
Open market or private sale
|
Direct |
4,817
-3.7%
|
$9,634
$2.07 P/Share
|
Jun 16
2023
|
Stephen Michael Moore SVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,509
-1.85%
|
$3,018
$2.07 P/Share
|
May 17
2023
|
Stephen Michael Moore SVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,781
-2.14%
|
$1,781
$1.98 P/Share
|
Last 12 Months Summary
Open market or private purchase | 10K shares |
---|
Open market or private sale | 61.5K shares |
---|